International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPercentage of Positive Biopsy Cores: A Better Risk Stratification Model for Prostate Cancer?
Introduction
The clinical T stage, Gleason score, and initial pretreatment prostate-specific antigen (iPSA) have been shown to be independent predictors of biochemical failure (BF) after definitive radiotherapy (RT) (1) and constitute the most commonly used risk-classification systems for prostate cancer (PCa), including that recommended by the National Comprehensive Cancer Network (NCCN; available from: www.nccn.org). However, those models do not perfectly predict the final outcome and include significant heterogeneity (2). The percentage of positive biopsy cores (PPC) and the presence of perineural invasion (PNI) as determined by transrectal ultrasound-guided biopsy have been suggested as potential prognostic factors to enhance the standard risk stratification for PCa patients treated with external beam RT (EBRT) 3, 4, 5. However, there are conflicting reports on their independent prognostic value, in addition to the established factors 6, 7. Recently, a multi-institutional study showed that the PPC would add minimal improvement to conventional stratification systems in predicting BF (8). Those previous studies have mostly concentrated on the correlation of the PPC or PNI to BF, which represents a surrogate for clinical outcomes (9). The potential prognostic value of PPC and PNI on potentially more clinically relevant outcomes such as locoregional recurrence (LRR), distant metastasis (DM), and overall survival (OS), require longer follow-up and have not been well quantified. The purpose of the present study was to retrospectively review a large cohort of patients with extended follow-up to clarify the clinical predictive value of PPC and PNI and to devise a new risk classification to improve on the existing stratification systems.
Section snippets
Methods and Materials
The eligible patients for the present study had clinical Stage T1c-T3N0M0 (1993 American Joint Committee on Cancer staging system) prostate adenocarcinoma (PCa) treated with definitive external beam radiotherapy (EBRT) with or without a high-dose-rate (HDR) brachytherapy boost at William Beaumont Hospital between 1993 and 2004. All cases were required to have the results of the transrectal ultrasound-guided biopsy available, with a minimum of four biopsy cores sampled. Patients with incomplete
Results
The characteristics of the entire cohort and comparisons between low (≤50%) and high (>50%) PPC are listed in Table 1. The median PPC was 33%, and 18% of patients had PNI. A high PPC was associated with younger age, more risk factors (T stage, Gleason score, iPSA, and PNI), and more aggressive treatment (increased use of high-dose RT and AD therapy). As seen in supplemental Table e1, a high PPC was associated with younger age for the intermediate- and high-risk groups and increased use of
Discussion
In the present study, we analyzed 1,056 PCa patients who were treated with modern RT techniques and found that the PPC is a powerful and independent predictor of highly relevant clinical outcomes. The association of the PPC with DM was especially robust and exists regardless of the use of AD therapy or high-dose RT. Furthermore, the prognostic effect of the PPC on DM appears to translate to a correlation with OS, especially for higher risk patients. This is remarkable considering patients with
Acknowledgments
The authors would like to thank Michelle Wallace, Kimberly Marvin, and Christina Mitchell for support with data management.
References (20)
- et al.
An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk
Int J Radiat Oncol Biol Phys
(2006) - et al.
The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
Int J Radiat Oncol Biol Phys
(2001) - et al.
Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy
J Urol
(2002) - et al.
Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy
Urology
(2007) - et al.
Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy
Urology
(2005) - et al.
Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer
Int J Radiat Oncol Biol Phys
(2003) - et al.
Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance
Int J Radiat Oncol Biol Phys
(2008) - et al.
Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control
Int J Radiat Oncol Biol Phys
(1996) - et al.
Improvement in dose escalation using the process of adaptive radiotherapy combined with three-dimensional conformal or intensity-modulated beams for prostate cancer
Int J Radiat Oncol Biol Phys
(2001) - et al.
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Int J Radiat Oncol Biol Phys
(2006)
Cited by (48)
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer
2020, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :However, for subsets of high-risk patients with a very high risk of PCSM, such as those with ≥50% PBC, who have a 2-fold increased risk compared to patients with <50% PBC, intensification of therapy may be appropriate to maximize cancer-specific outcomes. Other investigators have also attempted to further risk stratify patients with high-risk disease using clinical [17–22] and genomic data [23]. Our study represents the largest cohort of high-risk patients in which the role of PBC has been studied, though a few limitations of our analyses should be noted.
Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer
2015, BrachytherapyCitation Excerpt :After obtaining investigational review board approval, the records of 1294 men with clinically localized prostate cancer who underwent HDR brachytherapy, iodine (I)-125 LDR brachytherapy, or IMRT between January 2002 and September 2013 were reviewed. Patients were excluded if they had unfavorable intermediate-risk (19, 20) or high-risk (21) prostate cancer, or if they were treated with androgen deprivation therapy (ADT) (22, 23), combined IMRT and HDR brachytherapy or LDR brachytherapy, three-dimensional conformal radiation therapy (3DCRT), IMRT to a total dose other than 7400–8100 cGy in 37–45 fractions (7–10), HDR brachytherapy to a total dose other than 2700–2800 cGy in two fractions, or I-125 LDR brachytherapy to a total dose other than 14,500 cGy in one fraction (24). Seven patients treated with palladium-103 LDR brachytherapy to 12,500 cGy were excluded because of the small patient numbers.
Conflict of interest: none.